Company intelligence / Profile preview

Biocept

San Diego, California, United Statesprnewswire.com ↗

Ownership: Public · BIOCQ
Development stage: Commercial

Overview

Biocept developed proprietary diagnostic assays—most notably the CNSide™ test—for detecting and characterizing tumor cells and cfDNA in cerebrospinal fluid to help oncologists manage central nervous system metastases. Their CLIA-certified lab provided actionable biomarker data to guide treatment decisions. The company also offered liquid biopsy solutions for NSCLC and breast cancer using its OncoCEE technology platforms. As of early/mid–2024, Biocept ceased operations following an approved asset sale.

Therapeutic areas: Oncology
Modalities: Diagnostic assayDeviceRT-PCR-based test
Industry: Molecular Diagnostics

Financials

Market cap: $263
Total revenue: $589K
Enterprise value: $5M

Beyond the preview

Go deeper on Biocept.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocept.

Explore the full profile